Foundayo (Orforglipron) Tablets
Foundayo (orforglipron) is a breakthrough once-daily oral GLP-1 weight loss tablet. Designed as a small non-peptide molecule, it brings potent GLP-1 appetite suppression and up to 26% clinical weight loss into a convenient daily pill — completely needle-free.
Foundayo Titration Tiers
New to Foundayo? All new patients begin on 0.8mg daily for Month 1.
Recommended for all new Foundayo patients (Month 1)
Foundayo tablets are purchased at cost price directly from the pharmacy, facilitated by Smiths Medical Group.
What is Foundayo (Orforglipron)?
Foundayo contains orforglipron, a small-molecule oral GLP-1 receptor agonist that delivers injection-level weight reduction in a daily tablet.
Active Ingredient
Contains orforglipron, an oral non-peptide GLP-1 receptor agonist that targets hunger centers in the brain.
How It Works
Stimulates natural satiety signals, delays stomach emptying, and significantly curbs food noise and cravings.
Daily Administration
Taken once daily as a convenient oral pill, offering extreme convenience for busy routines.
Suitability
Suitable for adults with obesity (BMI ≥ 30) or overweight adults (BMI ≥ 27) with weight-related conditions.
Proven Efficacy
Clinical studies demonstrate up to 26% body weight reduction, matching top injectable weight loss pens.
Safety & Tolerability
Mild, temporary digestive adjustment is common. Structured monthly dose titration ensures optimal comfort.
Foundayo Treatment & Dosing Schedule
Foundayo tablets are taken once daily. We follow a structured monthly escalation schedule to build dose strength smoothly while maintaining digestive comfort.
Month 1
Adaptation dose for Month 1.
Month 2
Increases appetite control.
Month 3
Enhances fullness signals.
Month 4
Sustains steady progression.
Month 5
Advanced titration step.
Month 6+
Max maintenance dose.
Foundayo Treatment Schedule Breakdown
| Timeline | Daily Dose | Clinical Milestone | Consultation & Review |
|---|---|---|---|
| Month 1 (Weeks 1–4) | 0.8mg daily | Body adaptation & initial appetite regulation | Initial £50 Nurse Assessment & baseline checks |
| Month 2 (Weeks 5–8) | 2.5mg daily | Noticeable satiety increase & food noise suppression | Monthly £35 Nurse Review & progress tracking |
| Month 3 (Weeks 9–12) | 5.5mg daily | Accelerated weight loss & metabolic optimization | Monthly £35 Nurse Review & dose adjustment |
| Month 4 (Weeks 13–16) | 9mg daily | Sustained body weight reduction progression | Monthly £35 Nurse Review & health re-check |
| Month 5 (Weeks 17–20) | 14.5mg daily | Advanced escalation phase toward target weight | Monthly £35 Nurse Review & tolerance check |
| Month 6+ (Week 21 onwards) | 17.2mg daily | Maximum licensed maintenance dose for long-term weight management | Ongoing monthly £35 maintenance reviews & repeat prescriptions |
Targeted Blood Panels for Optimised Weight Management
At Smiths Medical Group, we provide an enhanced level of clinical diligence. By incorporating comprehensive blood analysis before and during your weight loss journey, we ensure your treatment is precisely tailored, safe, and protective of your long-term metabolic health.
Weight Loss Commencement Profile
Conducted prior to starting weight management therapy to establish your baseline organ function, screen for underlying metabolic or hormonal factors, and ensure prescribing suitability.
What It Evaluates:
- Liver & Kidney Function: Confirms healthy organ clearance for weight loss medications.
- Full Glycaemic Assessment (HbA1c & Fasting Blood Sugar): Screens for undiagnosed insulin resistance or pre-diabetes.
- Comprehensive Lipid Profile: Evaluates cholesterol markers to track cardiovascular improvements over time.
- Thyroid Function (TSH & Free T4): Rules out underlying thyroid dysfunction that can suppress metabolic rate.
Weight Loss Monitoring Profile
Recommended periodically during active weight loss to track metabolic response, verify nutritional balance, and adjust your treatment parameters with objective clinical data.
Key Monitoring Clinical Benefits:
- Nutritional & Micronutrient Status: Checks key micronutrient and vitamin levels as dietary intake reduces.
- Metabolic Trend Tracking: Measures progress in blood glucose, triglycerides, and liver enzymes during weight reduction.
- Dose Optimisation: Informs decisions on dosage titration to ensure efficacy while minimising unwanted side effects.
- Physician & ANP Oversight: Provides clear objective markers for review by Matthew Smith (ANP) and Dr Iqbal (Medical Director).
Why Blood Monitoring Provides a Superior Standard of Care
Standard online weight loss services often issue prescriptions based solely on online questionnaires without objective health data. At Smiths Medical Group, offering dedicated Commencement and Monitoring Blood Profiles elevates your care to a premium clinical standard.
Identifies pre-existing organ or metabolic conditions before starting active medication.
Provides clear, objective biomarker metrics demonstrating internal health improvements alongside scale weight.
Conducted with expert review from Advanced Nurse Practitioner Matthew Smith and Medical Director Dr Iqbal.
Foundayo Tablets FAQs
Answered by Matthew Smith, Advanced Nurse Practitioner.
Start Your Foundayo Tablets Treatment Plan
Book your initial £50 consultation with Matthew Smith, Advanced Nurse Practitioner, to establish eligibility, complete baseline health checks, and start your oral orforglipron plan.
Smiths Medical Group Ltd